Skip to content
Resources

Explainers, sourced.

Short explainers on how Zenreps works — assembled from the same claim-audited copy as the rest of this site. Nothing here sits behind a form.

01Resources

How the gate decides

On the gated text channels — web chat and Telegram — a zenrep's reply is constructed and checked before it reaches the HCP: grounded in your MLR-approved corpus, verified claim by claim, fair-balanced, and written to an inspectable record. This page is the mechanism an MLR reviewer needs to sign off.

It can only speak approved material.

There's no general medical model improvising underneath. A zenrep cannot assert anything that isn't in your medically and legally approved source material — that corpus is the ceiling on what it can say.

Every claim is checked before it's delivered.

Each turn passes the pipeline: in scope, fair-balanced, grounded in an approved passage, and citable. Then, and only then, is it spoken.

It refuses rather than guesses.

When a claim can't be grounded in approved material, the gate is fail-closed: the zenrep declines, redirects, or routes the question to a human. Refusing correctly is treated as a success, not a failure.

Every turn is audit-traceable.

Each exchange records what was asked, what was answered, what the gate decided, and the exact approved passage it was anchored to — reconstructable for your compliance team any time, and exportable as CSV.

02Resources

The ROI arithmetic, sourced

The left column is published research on what one US field rep costs and can do, shown with each figure's year and source. The right column describes what a zenrep is structurally — properties of software, not measured performance. Zenreps is pre-launch and publishes no performance numbers it hasn't earned. A zenrep is a coworker, not a substitute: this table is about the work software should carry so your reps can carry the relationships.

Honesty notes

Figures are shown with their survey years and are not inflation-adjusted; several predate 2020 and are almost certainly higher in today's dollars. DePaul, Gallup, and Bridge Group figures are general sales-industry benchmarks, not pharma-specific. The ZS access data shown is from 2016, the most recent year we verified against a primary public source; access is widely reported to have tightened since. The MedCepts per-call figure is rep pay only. Rows marked structural are design properties of software, not measured performance — Zenreps is pre-launch and publishes no performance metrics of its own yet.

1. Arx Research — Compensation for Pharma Sales Representatives, District and Regional Sales Managers (published 2017; 67 respondents at 29 US life-science companies): arxresearch.com/compensation-for-pharma-sales-reps-dms-rms

2. ZS AccessMonitor 2016, via PR Newswire — As Doctors Keep Closing Doors on Pharma Reps: prnewswire.com/news-releases/as-doctors-keep-closing-doors-o…

3. The Bridge Group, 2016 Sales Development Metrics and Compensation Benchmark Report, via For Entrepreneurs (David Skok) — sales-industry SDR benchmark, not pharma-specific: forentrepreneurs.com/bridge-group-sales-development

4. MedCepts — Value of Pharmaceutical Rep Per Physician Visit; rep compensation only, not fully loaded: medcepts.com/pages/value-of-independent-pharmaceutical-reps

5. DePaul University Center for Sales Leadership — 2015–2016 Sales Effectiveness & Sales Acceleration Survey; general B2B sales, not pharma-specific: cdn2.hubspot.net/hubfs/3319111/ConnectLeader_June2017/PDFs/C…

6. Gallup — This Fixable Problem Costs U.S. Businesses $1 Trillion (2019): gallup.com/workplace/247391/fixable-problem-costs-businesses…

7. Cardata — Fleet Vehicles: What Do They Really Cost? (vendor worked example, Jeep Cherokee fleet program): cardata.co/blog/fleet-vehicles-real-cost

03Resources

Jurisdictions & posture

The gate adapts its rules to the market and the product class: Canada (PAAB / Health Canada) and the United States (FDA OPDP) today, for both drug and device. Additional jurisdictions are on the roadmap.

Do you support the EU and UK?

Not live today. The regulatory research is complete and provisional rulesets are drafted; counsel review and productization remain before any EU or UK tenant goes live. Canada (PAAB) and the US (OPDP) are live, and EU is a near-term priority.

Residency that fits the law.

Canadian tenants in ca-central-1 (Montreal) today; us-east-1 reserved for US tenants in-region, standing up as they onboard.

Posture, stated honestly.

HIPAA-ready — BAAs activate at our first paying US customer. We claim no certification badge we don't yet hold.

More explainers will appear here as we write them — each passes the same claim audit as the rest of this site before it is published.